• In recent days, DaVita highlighted stronger-than-expected first-quarter 2026 results, raised its earnings outlook, and saw analysts lift their profit and revenue estimates. The company is also rapidly scaling its value-based Integrated Kidney Care platform and AI-enabled scheduling, aiming to coordinate chronic kidney disease treatment more efficiently across care settings.
• Analysts had already been focusing on DaVita’s cost efficiencies, innovation, and international growth, and now we’ll assess how the upgraded earnings outlook and expanded value-based kidney care programs could influence that investment narrative.

Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

DaVita Investment Narrative Recap

To own DaVita, you really have to believe that stable dialysis demand and expanding value based kidney care can offset cost pressures and reimbursement headwinds. The latest upside earnings surprise and higher outlook support the near term catalyst around profitability, but they do not remove key risks such as pressured treatment volumes and reimbursement that may lag rising costs.

The most relevant update here is DaVita’s stronger than expected Q1 2026 results, with higher revenue, EPS and a raised earnings outlook. That improvement, alongside rapid growth in Integrated Kidney Care and AI enabled scheduling, feeds directly into the thesis that better efficiency and coordinated care could support margins and income streams even as the company manages ongoing volume and reimbursement challenges.

Yet beneath the stronger outlook, investors should still watch how reimbursement trends and treatment volumes might...

DaVita's narrative projects $15.7 billion revenue and $1.1 billion earnings by 2029. This requires 4.2% yearly revenue growth and a roughly $343.6 million earnings increase from $756.4 million today.

Uncover how DaVita's forecasts yield a $193.71 fair value, a 11% downside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming only about US$15.3 billion of revenue and roughly US$803.0 million in earnings by 2029, and they were far more concerned about issues like unpredictable Integrated Kidney Care profitability and payer mix than the recent earnings beat suggests, so it is worth remembering that reasonable people can look at the same business and reach very different conclusions that could shift again after this news.

Explore 3 other fair value estimates on DaVita - why the stock might be worth as much as $193.71!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your DaVita research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free DaVita research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DaVita's overall financial health at a glance.

Interested In Other Possibilities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Find 44 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.